Evidence map›Paper›PMID 32283582›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2020

[Serum MiRNA as Predictive and Prognosis Biomarker in Advanced Stage Non-small Cell Lung Cancer in Indonesia].

Arif R Hanafi, Achmad M Jayusman, Serafim Alfasunu, Ahmad H Sadewa, Dibyo Pramono, Didik S Heriyanto, Sofia M Haryana

Open access · greenAbstract read
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. The Effect of MiR320a on Lung Cancer.MicroRNA (Shariqah, United Arab Emirates) · 2024
    Review
  5. Article
  6. Review
  7. Molecular Beacon for Detection miRNA-21 as a Biomarker of Lung Cancer.International journal of molecular sciences · 2022
    Article
  8. Article
  9. Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021
    Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Arif R HanafiDepartment of Pulmonology, ''Dharmais'' Hospital National Cancer Center, Jakarta 11420, Indonesia.
Achmad M JayusmanDepartment of Pulmonology, ''Dharmais'' Hospital National Cancer Center, Jakarta 11420, Indonesia.
Serafim AlfasunuDepartment of Pulmonology, ''Dharmais'' Hospital National Cancer Center, Jakarta 11420, Indonesia.
Ahmad H SadewaFaculty of Medicine, Gadjah Mada University, Yogyakarta 55281, Indonesia.
Dibyo PramonoFaculty of Medicine, Gadjah Mada University, Yogyakarta 55281, Indonesia.
Didik S HeriyantoFaculty of Medicine, Gadjah Mada University, Yogyakarta 55281, Indonesia.
Sofia M HaryanaFaculty of Medicine, Gadjah Mada University, Yogyakarta 55281, Indonesia.
Universitas Gadjah Mada · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLung cancer is the most common cause of death in men in the world and in Indonesia where non-small cell carcinoma lung cancer (NSCLC) constitutes 85% of all lung cancer cases. The high mortality rate is due to a poor prognosis and is often diagnosed as having advanced stages. If it is known at the initial stage, the prognosis of lung cancer will be better. Prognosis can be predicted with a marker of prognostic biology, one of which is micro RNA (miRNA). This study aims to prove that serum miRNA can be predictive biological marker and prognosis in NSCLC patients in Indonesia.

methodsThis study was cohort retrospective among 52 subjects in "Dharmais" Hospital National Cancer Center. Sample was obtained from patients' serum. MiR-34, miR-148, miR-155 and miR-222 serum are measured through Real-Time PCR (qPCR). Data were analyzed and interpreted with descriptive analysis, bivariate analysis (Mann Whitney-U for two type of variables or Kruskal-Wallis for more than two type of variables. Kaplan-Meier analysis was used to know association between characteristic which are sociodemographic, performance status, clinico-pathology, and survival rate in miRNA expression.

resultsFrom this study, miRNA expression: miR-34 (46.15%), miR-148 (23.08%), miR-155 (40.38%) and miR-222 (32.69%). Performance status score was statistically significant correlation with miR-148 (P=0.049) and miR-222 (P=0.018). High miR-34 is associated with multiple M1b metastatic type (P=0.020), cancer cell type (adenocarcinoma, P=0.009) and adenocarcinoma epidermal growth factor receptor (EGFR) mutation (negative, P=0.031). There was a significant correlation between the high miR-222 as a poor prognosis in advanced stage NSCLC with M1b metastasis (Median Survival/MS: 27 d, P=0.049) and positive EGFR mutations (MS: 74 d, P=0.049) and correlation of miR-155 with adenocarcinoma (MS: 69 d, P=0.034) and positive EGFR gene mutations (MS: 58 d, P=0.023).

conclusionsHigh miR-34 expression in advanced stage NSCLC is the predictive factor for multiple metastatic, adenocarcinoma cell type and adenocarcinoma negative EGFR mutation. High expression of miR-155 and miR-222 are poor prognoses, especially high miR-222 found in metastasis M1b and positive EGFR mutation and miR-155 found in adenocarcinoma and positive EGFR gene mutations. Further studies regarding correlation between miRNA and survival rate are needed.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCarcinoma, Non-Small-Cell LungFemaleHumansIndonesiaLung NeoplasmsMaleMicroRNAsMiddle AgedRetrospective StudiesSurvival RateBiomarkers, TumorMicroRNAsMIR222, humanMIRN148 microRNA, humanMIRN155 microRNA, humanMIRN34 microRNA, humanAdvanced stage NSCLCSerum miRNASurvival

Identifiers

PMID32283582
PMCPMC7260391
OpenAlexW3015912822

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.